- Conditions
- Chronic Illness, NYHA Class II-IV Heart Failure
- Interventions
- ADAPT HF
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 2,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
- Conditions
- Heart Failure, Congestive
- Interventions
- GSK716155, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 12
- States / cities
- Savannah, Georgia • Metairie, Louisiana • Auburn, Maine + 9 more
- Conditions
- Heart Failure NYHA Class II
- Interventions
- EAA mixture, Placebo (whey protein)
- Dietary Supplement
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
- Conditions
- Heart Failure, NYHA Class II Heart Failure, NYHA Class III Heart Failure
- Interventions
- Limiting Ultraprocessed Food (UPF) in Diet
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Interventions
- Cordella™ Pulmonary Artery Sensor System
- Device
- Lead sponsor
- Endotronix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
- Conditions
- Heart Failure
- Interventions
- Eplerenone
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 2,743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more
- Conditions
- Systolic Heart Failure
- Interventions
- Probenecid 1 gr oral twice daily, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Congestive Heart Failure
- Interventions
- Oxypurinol
- Drug
- Lead sponsor
- Advanz Pharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 4
- States / cities
- Oceanside, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Chronic Heart Failure
- Interventions
- Enalapril, Aliskiren
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 58
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
- Interventions
- Cardiopulmonary exercise test, Echocardiogram
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- We Chatt communication tool, Usual/standard care
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Congestive Heart Failure
- Interventions
- MCC-135, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 47 more
- Conditions
- Congestive Heart Failure(CHF)
- Interventions
- Hawthorn supplement, Ketones, Placebo Control
- Dietary Supplement · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
- Interventions
- IVC Sensor
- Device
- Lead sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 9
- States / cities
- Chula Vista, California • Sacramento, California • Jacksonville, Florida + 6 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class I
- Interventions
- Computerized Cognitive Training with Brain HQ, Computerized Crossword Puzzles
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Interventions
- Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Heart Failure
- Interventions
- Thyroid hormone T3, Control Group
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Heart Failure
- Interventions
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Interventions
- CardioMEMS HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Heart Failure, Congestive
- Interventions
- ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination
- Drug · Procedure · Behavioral
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 22
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 17 more